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Background: The cytotoxicity of radiotherapy and chemotherapy can be enhanced by modulating DNA repair.
PARP is a family of enzymes required for an efficient base-excision repair of DNA single-strand breaks and
inhibition of PARP can prevent the repair of these lesions. The current study investigates the trimodal combination
of ABT-888, a potent inhibitor of PARP1-2, ionizing radiation and temozolomide(TMZ)-based chemotherapy in
glioblastoma (GBM) cells.
Methods: Four human GBM cell lines were treated for 5 h with 5 μM ABT-888 before being exposed to X-rays
concurrently with TMZ at doses of 5 or 10 μM for 2 h. ABT-8880s PARP inhibition was measured using
immunodetection of poly(ADP-ribose) (pADPr). Cell survival and the different cell death pathways were examined
via clonogenic assay and morphological characterization of the cell and cell nucleus.
Results: Combining ABT-888 with radiation yielded enhanced cell killing in all four cell lines, as demonstrated by a
sensitizer enhancement ratio at 50% survival (SER50) ranging between 1.12 and 1.37. Radio- and chemo-sensitization
was further enhanced when ABT-888 was combined with both X-rays and TMZ in the O6-methylguanine-DNA-
methyltransferase (MGMT)-methylated cell lines with a SER50 up to 1.44. This effect was also measured in one of the
MGMT-unmethylated cell lines with a SER50 value of 1.30. Apoptosis induction by ABT-888, TMZ and X-rays was also
considered and the effect of ABT-888 on the number of apoptotic cells was noticeable at later time points. In
addition, this work showed that ABT-888 mediated sensitization is replication dependent, thus demonstrating that
this effect might be more pronounced in tumour cells in which endogenous replication lesions are present in a
larger proportion than in normal cells.
Conclusions: This study suggests that ABT-888 has the clinical potential to enhance the current standard treatment
for GBM, in combination with conventional chemo-radiotherapy. Interestingly, our results suggest that the use of
PARP inhibitors might be clinically significant in those patients whose tumour is MGMT-unmethylated and currently
derive less benefit from TMZ.
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Glioblastoma (GBM), or WHO grade IV glioma, is the
most common and malignant of all primary brain tu-
mours, accounting for the most years of human life lost,
per patient, than any other form of adult cancer [1]. Des-
pite recent advances in combined modality treatment with
surgery, radiotherapy and temozolomide (TMZ) chemo-
therapy, the outlook for patients is bleak with a median
survival of 12–14 months [2].
The key cytotoxic and mutagenic lesion induced by TMZ
is considered to be the formation of O6-methylguanine
(O6-MeG). Transcriptional silencing of the repair protein
encoded by the O6-methylguanine-DNA-methyltransferase
(MGMT) gene allows genotoxic damage induced by TMZ
to persist, and is predictive of treatment outcome and pa-
tient survival [3]. Only 5% of all DNA methylation induced
by TMZ occurs at the O6 position of guanine. N7-
methylguanine and N3-methyladenine account for 60-70%
and 10-20% of the total methyl adducts, respectively. These
lesions, together with radiation induced single stranded
breaks (SSBs), are recognised and processed by the base ex-
cision repair (BER) pathway. The enzyme poly(ADP-ribose)
polymerase (PARP) plays a key role in BER, by binding to
processed SSBs, and facilitating recruitment of X-ray repair
cross-complementing 1 (XRCC1). XRCC1 intervenes as a
scaffold protein recruiting other DNA polymerases and
DNA ligases.
Recent data suggest that defects in the BER system may
have particular impact on the response to both ionizing
radiation and TMZ [4]. On this basis, PARP inhibition has
been extensively explored as a potential approach to derive
additional cytotoxicity from radiotherapy and DNA-
methylating agents.
ABT-888 (Veliparib) is a novel, orally bioavailable, and
potent PARP inhibitor developed by Abbott laboratories
from a modification of a benzimidazole ring. ABT-888
inhibits both PARP-1 and PARP-2 enzymes with an inhi-
bitory constant, Ki, of 5.2 and 2.9 nmol/l, respectively
[5]. Preclinical pharmacokinetic studies reported oral bio-
availabilty values between 56 to 92% and, more import-
antly, ABT-8880s ability to cross the blood brain barrier
(BBB) with plasma to brain ratio of 3:1 as evaluated in
tumour-bearing rats [5].
This study investigates the sensitizing effects of ABT-
888 in combination with ionizing radiation and TMZ on
four human GBM cell lines. It is the first in vitro study
to investigate possible synergy between these three
agents, and to assess the influence of MGMT promoter
methylation status on tumour response.
Methods
Cell culture
Four human GBM cell lines (T98G, LN18, U87 and
U251) were used in this study. T98G cells were providedby Mick Woodcock, Gray Institute for Radiation
Oncology and Biology, Oxford, UK; U87 and U251 cells
were obtained from the Health Protection Agency
Culture Collections (HPACC, Wiltshire, UK) and LN18
from the American Type Culture Collection (ATCC,
Middlesex, UK). All cell lines were confirmed Myco-
plasma free before use. The cells were cultured as previ-
ously described in Barazzuol et al. [6].
MGMT Western blot analysis
Whole cell lysates were prepared in assay buffer (20 mM
Tris, 100 mM NaCl, 5 mM EDTA, 1 mM EGTA, 5 mM
β-mercaptoethanol; pH 7.5) and passed repeatedly
through a 21-gauge needle for lysis. The cell lysate was
then centrifuged at 13,000 g for 20 min at 4°C. Protein
concentration was measured using the Bradford assay
(Thermo Scientific, Northumberland, UK). Whole-cell
lysates (30 μg) were mixed with 5 × SDS loading buffer
and boiled for 5 min prior to SDS-PAGE on Bio-Rad
precast gel (Bio-Rad, Hertfordshire, UK), run at a con-
stant voltage of 125 V for 1.5 h. Semi-dry transfer was
done to PVDF membrane for 30 min, using the Bio-Rad
Trans-Blot Turbo transfer system. After blocking in 5%
skimmed milk in TBST (20 mM Tris–HCl, 150 Mm
NaCl, 0.1% Tween 20; pH 7.6) for 5 h, the membrane
was incubated at 4°C overnight with primary antibody
against MGMT (2739; Cell Signaling Technology, Dan-
vers, US) at 1:250 dilution in TBST. Bound antibodies
were visualised with peroxidase-conjugated goat anti-
rabbit IgG (1:2000 in TBST) using the Bio-Rad Immun-
Star Western C chemiluminescence kit according to the
manufacturer’s instructions.Drug treatment
TMZ was provided by Fluka (Sigma-Aldrich, Dorset, UK)
and reconstituted in dimethylsulfoxide (DMSO) to a final
concentration not exceeding 0.1% (at this concentration,
DMSO alone had no effect on cell viability). TMZ was ad-
ministered at different concentrations and exposure times
according to the type of experiment. For single-agent
TMZ cytotoxicity, cells were exposed continuously to in-
creasing concentrations of TMZ according to the MGMT
status. For combined TMZ, ABT-888 and radiation, TMZ
was administered in 5 μM for the MGMT-methylated cells
and 10 μM for the MGMT-unmethylated cells for a total
exposure time of 2 h, including 1 h before irradiation.
After 2 h with TMZ, the medium was replaced.
ABT-888 was supplied by Enzo Life Sciences
(Farmingdale, US) and reconstituted in Milli-Q water. For
single ABT-888 cytotoxicity, cells were incubated continu-
ously with increasing concentrations of ABT-888 from
0.002 to 50 μM. For the combined experiments with
TMZ and radiation, ABT-888 was used at 5 μM and
Figure 1 Western blot analysis showing the MGMT protein
levels and the protein loading control in a panel of four GBM
cell lines (LN18, T98G, U87 and U251).
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ation (2 h exposure time for TMZ).
Irradiation
X-ray irradiation was performed using a Gulmay machine
operating at 250 kVp with a dose rate of 0.65 Gy/min
(Royal Surrey County Hospital, Guildford, UK). Cells were
grown in 6- well plates and incubated for 5 h before irradi-
ation. Cells were then exposed at room temperature to
doses between 1 to 6 Gy.
Clonogenic survival assay
Clonogenic assay was used to evaluate single drug cytotox-
icity (TMZ and ABT-888) and combined treatments (ABT-
888, TMZ and X-rays). Cells were grown in 6-well plates
and after treatment incubated for up to 14 days. Colonies
were fixed with 50% ethanol in PBS and then stained with
5% crystal violet in PBS (Sigma-Aldrich, Dorset, UK). The
colonies with more than 50 cells were counted and the sur-
vival fractions were determined taking into consideration
the plating efficiency for all treatment modalities based on
three separate experiments.
pADPr immunofluorescence quantification
Cells were grown in polystyrene dishes at a concentration
of 5 × 105 cells/ml, and pre-treated with 5 μM ABT-888
for 2 h before treatment with 20 mM hydrogen peroxide
(H2O2) for 10 min with or without 5 μM ABT-888. Cells
were then washed with ice-cold PBS and fixed with ice-
cold methanol/acetone (50:50) for 5 min. Samples were
then washed twice with ice-cold PBS and incubated with
1% BSA in PBS for 30 min, before being probed for
pADPr adding an anti-pADPr antibody (ab14459; Abcam,
Cambridge, UK) at a dilution of 1:400 in 1% BSA in PBS
for 1 h at room temperature. Cells were then washed three
times with PBS before adding FITC-conjugated goat anti-
mouse IgG secondary antibody (Millipore, Watford, UK)
at a dilution of 1:400 in 1% BSA in PBS for 1 h protected
from light. Cells were washed three times with PBS before
adding 2.5 μg/ml 40,6-diamidino-2-phenylindole dilactate
(DAPI; Invitrogen, Oregon, US) in PBS for 1 min. Finally,
round coverslips were mounted with 10 μl of ProLong
Gold anti-fade reagent (Invitrogen, Oregon, US). Samples
were analysed using the microscope described in a separ-
ate paper [7] at ×40 magnification. Image processing was
performed using ImageJ (v1.44p, National Institutes of
Health, Bethesda, US) and the pADPr signal intensity was
measured as the mean gray value within selected regions
of interest (ROI) corresponding to the relative DAPI-
stained nuclei.
Cell death analysis
Cells were treated as described above and collected at
different time points after irradiation (1, 5, 10, 24, 48and 72 h for 3 Gy; and, 24 and 48 h for 2 and 4 Gy) and
fixed in 1% formaldehyde (Sigma-Aldrich, Dorset, UK).
Samples were stained with 10 μg/ml acridine orange and
8.3 μg/ml Hoechst 33342 (Invitrogen, Oregon, US). The
morphological characterization of cell death included
apoptosis, necrosis and mitotic catastrophe (Additional
file 1). Between 200 and 400 cells were scored for each
sample.
Statistical analysis
All experiments were performed in either duplicate or
triplicate. The error bars represent the standard error
among the different experiments. The sensitizer enhance-
ment ratio (SER) was used to evaluate the drug-radiation
interaction. Its value was estimated from fitting to the
Linear-Quadratic (LQ) model as follows:
SERx% ¼ dx% no drugð Þdx% drugð Þ
where dx%(no drug) is the radiation dose (Gy) required to
produce ×% cell survival without drug and dx%(drug) in
presence of drug (i.e. TMZ and/or ABT-888). SER was cal-
culated at doses related to surviving fractions of 37
and 50%.
Statistical significance was determined using a two-
sample t-test and a p value less than 0.05 was considered
significant.
Results
Cell sensitivity to TMZ and ABT-888
Our panel of four GBM cell showed heterogeneous
MGMT protein expression. LN18 and T98G showed high
expression levels of MGMT; whereas, the other two cell
lines, U87 and U251, had undetectable levels of MGMT
(Figure 1). The EC50 values for TMZ ranged between 9.64
(U87) to 346.65 μM (LN18) (Figure 2). MGMT-
unmethylated LN18 and T98G cell lines showed the
highest resistance to TMZ, confirming that MGMT is an
important predictive factor of response to TMZ [3].
The EC50 values for ABT-888 were 19.64, 22.02, 6.44
and 21.9 μM for LN18, T98G, U87 and U251, respectively
Figure 3 Cell survival curves of MGMT-unmethylated cell lines,
LN18 and T98G, and MGMT-methylated cell lines, U87 and U251.
Cells were exposed continuously to increasing concentrations of ABT-
888 alone (0.002-10 μM). The data were fitted with the Hill equation
(solid line) in order to estimate the EC50 values. Error bars indicate the
standard error of at least three independent experiments.
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methylation status and ABT-888 sensitivity. However,
MGMT-methylated, p53 wild type U87 cells were signifi-
cantly more sensitive to prolonged exposure of ABT-888
than the other cell lines.
A concentration of 5 μM ABT-888 was then used in
the subsequent experiments. This concentration of ABT-
888 for an exposure time of 5 h did not yield consider-
able cellular cytotoxicity (Figure 4).
Evaluation of pADPr synthesis in the presence of ABT-888
Upon DNA damage, PARP catalyzes the formation of the
polymer pADPr, therefore PARP activity was assessed by
measuring the level of pADPr. Under normal conditions,
all cells displayed low basal levels of pADPr. Treatment
with 20 mM H2O2 induced PARP activation as demon-
strated by a rapid increase of pADPr synthesis. In contrast,
cells treated with 5 μM ABT-888 for 2 h before exposure
to H2O2 showed no significant difference in pADPr as
compared to basal levels (Figure 5). These data validated
that the dose of ABT-888 chosen was suitable to inhibit
PARP activity.Clonogenic survival after treatment with X-rays, TMZ and
ABT-888
Cell survival was investigated after combined treatment
with ABT-888, TMZ and X-rays (Figure 6). No signifi-
cant interaction between X-rays and TMZ for the doses
chosen (5 and 10 μM for the MGMT-methylated and -
unmethylated cell lines, respectively) could be observed
in all four cell lines. The SER50 and SER37 values wereFigure 2 Cell survival curves of MGMT-unmethylated cell lines,
LN18 and T98G, and MGMT-methylated cell lines, U87 and
U251. Cells were exposed continuously to increasing concentrations
of TMZ alone. The data were fitted with the Hill equation (solid line)
in order to estimate the EC50 values. Error bars indicate the standard
error of at least three independent experiments.near unity and the p values calculated at the dose of 50
and 37% survival were all greater than 0.24 (Table 1).
The combination of X-rays and ABT-888 led to a sub-
stantial radiosensitizing effect with SER50 ranging between
1.13 and 1.37, and SER37 between 1.12 and 1.31. This was
also accompanied by an increase in α parameter of the LQ
model (Table 1). The highest radiosensitization was found
in LN18 and U251 cell lines, as demonstrated by SER50
values above 1.28. T98G and U87 cell lines displayed only
a modest effect of ABT-888 on the radiation survival curveFigure 4 Plating efficiency (PE) for four GBM cell lines
incubated for 5 h with or without 5 μM ABT-888. No significant
difference in survival relative to untreated cells was observed (p > 0.8).
Figure 5 (a) Immunofluorescence detection of pADPr in GBM cells exposed to 20 mM H2O2 with or without 5 μM ABT-888; scale bar at
bottom right = 10 μm. (b) Fluorescence intensity quantification of the pADPr signal estimated using ImageJ (v1.44p, National Institutes of
Health, Bethesda, US). Error bars indicate the standard error among 100 cell nuclei.
Figure 6 Cell survival curves of MGMT-unmethylated LN18 (a) and T98G cells (b), and MGMT-methylated U87 (c) and U251 cells (d).
Cells were treated with 5 μM ABT-888 for 5 h before being exposed to either 5 (c ,d) or 10 (a, b) μM TMZ for 2 h, including 1 h before and 1 h
after irradiation. Symbols represent mean ± standard error of at least three independent experiments.
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Table 1 Radiobiological parameter values
Treatment LN18 T98G U87 U251
α (Gy-1) β (Gy-2) SER50
(p)
SER37
(p)
α (Gy-1) β (Gy-2) SER50
(p)
SER37
(p)
α (Gy-1) β (Gy-2) SER50
(p)
SER37
(p)
α (Gy-1) β (Gy-2) SER50
(p)
SER37
(p)
X-rays 0.08 ±
0.02
0.04 ±
0.01
- - 0.04 ±
0.02
0.05 ±
0.01
- - 0.15 ±
0.04
0.04 ±
0.01
- - 0.01 ±
0.02
0.06 ±
0.01
- -
X-rays + 5/10 μM TMZ 0.13 ±
0.02
0.04 ±
0.01
1.08
(0.32)
1.06
(0.36)
0.02 ±
0.01
0.05 ±
0.01
0.95
(0.52)
0.96
(0.50)
0.12 ±
0.05
0.05 ±
0.01
0.99
(0.93)
1.01
(0.92)
0.04 ±
0.03
0.06 ±
0.01
1.08
(0.24)
1.06
(0.30)
X-rays + 5 μM ABT-888 0.18 ±
0.02
0.04 ±
0.01
1.28
(0.01)
1.23
(0.01)
0.12 ±
0.02
0.04 ±
0.01
1.16
(0.25)
1.12
(0.20)
0.21 ±
0.02
0.04 ±
0.01
1.13
(0.16)
1.12
(0.17)
0.12 ±
0.02
0.07 ±
0.01
1.37
(0.002)
1.31
(0.002)
X-rays + 5 μM ABT-888 + 5/10
μM TMZ
0.16 ±
0.01
0.05 ±
0.01
1.25
(0.02)
1.21
(0.01)
0.15 ±
0.01
0.04 ±
0.01
1.30
(0.03)
1.24
(0.01)
0.33 ±
0.02
0.02 ±
0.01
1.30
(0.03)
1.24
(0.04)
0.20 ±
0.01
0.05 ±
0.01
1.44
(0.003)
1.35
(0.001)
Mean values of α, β, SER50 and SER37 (including p values) of MGMT-unmethylated LN18 and T98G cells, and of MGMT-methylated U87 and U251 cells, estimated by fitting the cell survival to the LQ model.
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Figure 7 Percentages of apoptotic cells in MGMT-unmethylated LN18 (a) and MGMT-methylated U87 cells (b) up to 72 h after
irradiation. Cells were exposed for 5 h to 5 μM ABT-888 before being treated with 5 (b) or 10 (a) μM TMZ for 2 h and irradiated with
3 Gy X-rays. Dose–response percentages of apoptotic cells in MGMT-unmethylated LN18 (c, d) and MGMT-methylated U87 cells (e, f). Cells were
exposed to 2, 3 and 4 Gy X-rays and fixed at 24 and 48 h after irradiation. Error bars indicate the standard error of two independent experiments.
Please note the scale change on the Y-axis of the graphs. P values relatively to the control are also shown.
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radiosensitizing effect of ABT-888 was independent of the
MGMT methylation status.
The triple combination of X-rays, TMZ and ABT-888
was more effective than single agents in all four cell lines
and appeared to be more pronounced in the two
MGMT-methylated cell lines. Higher levels of ABT-888-mediated sensitization to X-rays and TMZ were ob-
served in both U87 and U251 cell lines with SER50 of 1.30
and 1.44, respectively. Further sensitization was also ob-
served in the MGMT-unmethylated T98G cell line with
SER50 of 1.30 for all three agents compared to 1.16 with
the dual combination of X-rays and ABT-888. However,
no additional enhancement was observed with LN18 cells
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888 (SER50 of 1.28 compared to SER50 of 1.25; Table 1).
Induction of apoptosis by X-rays, TMZ and ABT-888
Time-course measurements of apoptosis were undertaken
after exposure to a radiation dose of 3 Gy in combination
with TMZ and ABT-888 (Figure 7). The induction of
apoptosis increased with time reaching a maximum level
at 72 h in the range of 11.21 to 14.28% and 11.77 to
13.24% for LN18 and U87 cells, respectively (p<0.04
Figure 7a; p = 0.22 Figure 7b).
In MGMT-unmethylated LN18 cells, a single early
apoptotic peak was observed 5 h after treatment with X-
rays, TMZ and ABT-888, as demonstrated by the amount
of apoptotic cells that was greater (8.27%) than with X-
rays alone (5.89%). However, this disproportion was not
statistically significant (p = 0.23 Figure 7a). This peak was
not seen in the MGMT-methylated U87 cells. Apoptotic
responses for U87 cells were very similar for the different
treatment combinations (p > 0.05 Figure 7a).
In addition, dose–response measurements were per-
formed at 24 and 48 h after irradiation with 2, 3 and 4
Gy (Figure 7). Both LN18 and U87 cells showed a dose-
dependent increase in radiation-induced apoptotic cells.
At 48 h, the trimodal treatment seemed to be more effect-
ive than single modalities. In particular, in U87 there was a
significant difference in apoptosis after treatment with 4
Gy, TMZ and ABT-888 as compared with radiation alone
(p < 0.04 Figure 7f).
The sensitizing effect of ABT-888 to TMZ and X-rays
may involve other cell death pathways distinct from apop-
tosis. Therefore, mitotic catastrophe and necrosis were
evaluated at 72 h after treatment with 3 Gy X-rays, TMZ
and ABT-888. A minimal amount of cells (< 3%) undergo-
ing mitotic catastrophe and necrosis was seen in both
LN18 and U87 cells for all treatment combinations (data
not shown).
Discussion
PARP inhibition is a promising mechanism for enhancing
efficacy of chemoradiation therapy. A number of PARP in-
hibitors are currently being assessed in clinical trials, in-
cluding ABT-888 for which six phase I-II clinical trials
exist in patients with brain or central nervous system
(CNS) tumours [8].
To date, only one preclinical study has looked at the
trimodal combination of PARP inhibitor ABT-888 with
TMZ and X-rays in GBM xenografts [9]. The present
in vitro study suggests that ABT-888 enhances the effects
of radiation. A further sensitization has also been shown
when ABT-888 was added to both TMZ and X-rays. Al-
though the maximum enhancement in cell killing was
obtained in MGMT-methylated cell lines, MGMT expres-
sion did not prevent ABT-888-mediated sensitization. Thisstudy also indicates that PARP inhibition has an effect on
the apoptotic cell death pathway.
ABT-888 is a potent inhibitor of PARP
Our study confirmed ABT-8880s favourable pharmacoki-
netic profile and effective attenuation of pADPr formation
at a non-cytotoxic concentration of 5 μM in all four GBM
cell lines. These results concur with previously reported
data by Albert et al. [10] on H460 lung carcinoma cells
and Horton et al. [11] on leukaemia cells, in which an op-
timal dose of 5 μM ABT-888 was determined for in vitro
models. Importantly, phase 0-I clinical trials have
established the achievable area under the plasma concen-
tration time curve for ABT-888 to be 1.46 μM at an initial
dose of 10 mg administered orally twice a day (BID) show-
ing that μM concentrations are clinically achievable [12,13].
The EC50 values for ABT-888 did not show strong varia-
tions among the cell lines, except for the MGMT-
methylated, p53 wild-type U87 cell line (EC50 = 6.44 μM).
It would be of interest to elucidate the relationship be-
tween PARP and p53 as all the other cell lines (LN18,
T98G and U87) were mutant for p53. Previous reports
suggest that PARP-1 is a critical regulator of the p53 re-
sponse to DNA damage [14,15]. This observation might
be relevant to the clinical treatment of GBM as about a
third of GBMs have p53 mutations [16].ABT-888 enhances radiation response regardless of the
MGMT status
The results demonstrated that exposure to 5 μM ABT-888
for 5 h before irradiation resulted in significant radiosen-
sitization of all four cell lines (SER50 = 1.12-1.37), regardless
of the MGMT methylation status (Figure 6). The
radiosensitizing effect of ABT-888 seemed to be inversely
related to the cell population doubling time. Indeed, this ef-
fect was more pronounced in LN18 and U251 cells with
SER50 of 1.28 and 1.37, respectively, and doubling times of
24 h. This is relevant in the case of brain tumours as the
surrounding normal tissue is composed of cells which pro-
liferate slowly or not at all [17-19].
Consistent with the current study, Albert et al. [10]
found that 6 h exposure to 5 μM ABT-888 sensitizes lung
cancer H460 cells to radiation with a SER25 of 1.27. This
was also accompanied by a delay in the resolution of γ-
H2AX foci at 6 h after irradiation. Similarly, Efimova et al.
[20] noted that ABT-888 markedly enhances persistence
of γ-H2AX foci in breast cancer cells up to 24 h after ir-
radiation. Liu et al. [21] also showed that ABT-888 impairs
the resolution of DSBs remaining at 24 h in the malignant
prostate cancer 22RV1 cell line. Altogether, these data
suggest that the radiosensitizing effect of ABT-888 is likely
to be the consequence of an interaction between
unrepaired SSBs and collapsed DNA replication forks
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cycle checkpoint system which in turn initiates cell cycle
arrest, DNA repair or cell death [4].
In vivo, one study using an HCT-116 colon model
reported that ABT-888 is an effective radio-sensitizer
[5]. However, Clarke et al. [9] reported no effect of ABT-
888 addition on survival relative to radiotherapy alone
on two primary GBM xenografts.ABT-888 further enhances response to TMZ plus X-rays in
MGMT-methylated cell lines
Stratification of clinical treatment response by MGMT-
methylation status demonstrates poorer outcomes for
patients with MGMT-unmethylated tumours. An agent
capable of enhancing radiation response in this group
would be a valuable new treatment. Our study suggests
that trimodal treatment with ABT-888, TMZ and X-rays
seems to mostly enhance cell killing in the MGMT-
methylated U87 and U251 cell lines (Figure 6). The rela-
tive SER50 increased from 1.13 and 1.37 with ABT-888
plus X-rays to 1.3 and 1.44 with ABT-888, TMZ and X-
rays for U87 and U251 cell lines, respectively. These SER
values lie in the range of those obtained with platinum-
and taxane-based chemotherapy for different tumour
types and end points [22,23].
An increase in SER50 was also noted in the MGMT-
unmethylated T98G cells. This observation suggests that
the MGMT methylation status is not an absolute pre-
dictor of response to trimodal treatment. However, there
is disagreement in the literature on whether ABT-888-me-
diated sensitization to TMZ is independent of the MGMT.
Palma et al. [24] reported that neither MGMT nor mis-
match repair (MMR) precluded sensitivity to ABT-888
plus TMZ in several tumour types. Likewise, Horton et al.
[11] suggested that ABT-888 chemo-potentiation in leu-
kaemia and colon cancer cells might not depend on
MGMT activity. However, the authors acknowledged that
ABT-888 was less effective in the presence of elevated
MGMT levels. In contrast, Clarke et al. [9] showed that
not all GBM tumours respond equally to ABT-888 plus
TMZ, suggesting that ABT-888 may not overcome
tumour resistance to TMZ.
Furthermore, it would be of interest to explore different
treatment schedules, in particular a different duration of
ABT-888 and TMZ exposure before irradiation, and
whether TMZ might further sensitize the cells to radi-
ation. To date, a growing number of preclinical studies
have looked at the effects of TMZ on the radiosensitivity
of GBM cell lines reporting opposing results. While some
studies support a synergistic effect between concurrent
TMZ and radiation in favour of radiosensitization [25-28],
other papers reported independent cell killing [29-32]. It is
likely that the optimal schedule of drug administration forTMZ-mediated radiosensitization is the one that will also
result in an increased efficiency of ABT-888.
ABT-888 has an effect on apoptotic response
Apoptosis is an energy dependent form of cell death, and
as such, it requires adenosine-50-triphosphate (ATP). The
principal substrate of PARP is nicotinamide adenine di-
nucleotide (NAD+), which is required to catalyse pADPr
in the presence of DNA damage. In turn, a reduction in
NAD+ leads to a depletion of ATP. By preventing ATP
loss, inhibition of PARP should enhance the apoptotic re-
sponse to genotoxic damage. Our results confirm that the
combination of ABT-888 with either radiation or radiation
plus TMZ had an effect on the apoptotic response, notice-
able at later time points after treatment (Figure 7).
Similarly, Albert et al. [10] assessed apoptosis after
treatment with 5 μM ABT-888 and radiation on a lung
cancer H460 cell line, reporting a 2.8-fold increase in
apoptosis compared to control. Additionally, in vivo
TUNEL analysis on sections of H460 tumour models
showed a 65% increase in apoptosis when ABT-888 was
added to radiotherapy. In a separate study, Liu et al. [33]
showed that 5 μM ABT-888 co-treatment with the DNA
alkylating agent N-methyl-N’-nitro-N-nitrosoguanidine
(MNNG) induced activation of caspase-9 and caspase-3
and increased apoptosis in cervical cancer HeLa cells by
preventing ATP loss. Nowsheen et al. [34] reported a
significant increase in apoptosis when head and neck
cancer cells were treated with cetuximab and ABT-888.
They hypothesized that apoptosis by PARP inhibition
was due to intracellular stress signals, which resulted in
the activation of the apoptotic intrinsic pathway. More
recently, Huehls et al. [35] reported that ABT-888 pro-
moted apoptosis in ovarian cancer cells treated with 5-
fluorodeoxyuridine (FdUrd) but not with 5-fluorouracil
(5-FU).
Conclusions
In summary, this study showed that modulating DNA
repair by selectively inhibiting PARP is a potential thera-
peutic approach to enhance standard treatment in pa-
tients with GBM. The most attractive use of PARP
inhibitors might be in those patients whose tumour is
MGMT-unmethylated and currently derive less benefit
from chemo-radiotherapy.
Additional file
Additional file 1: Morphological classification of cells after dual
fluorescent staining with acridine orange (AO) and Hoechst 33342
(HO). Representative photographs of apoptosis (a), mitotic catastrophe
(b) and necrosis (c).
Competing interests
The authors declare that they have no competing interest.
Barazzuol et al. Radiation Oncology 2013, 8:65 Page 10 of 11
http://www.ro-journal.com/content/8/1/65Authors’ contributions
LB carried out the experiments, analysis and interpretation of data, and
drafted the manuscript. RJ participated in the study conception and design,
and drafting of the manuscript. LM participated in the Western Blot analysis
and revision of the manuscript. NGB and NFK were involved in the data
interpretation and drafting of the manuscript. JCGJ participated in the pADPr
immunofluorescence quantification and data interpretation. KJK was involved
in the study coordination and drafting of the manuscript. All authors read
and approved the final manuscript.Acknowledgements
We are grateful to the Royal Surrey County Hospital for providing the time
and supervision in the X-ray experiments. The research leading to these
results has received funding from the European Community’s Seventh
Framework Programme ([FP7/2007-2013] under grant agreement no 215840–2).
NGB is supported by the National Institute of Health Research Cambridge
Biomedical Research Centre, UK.
Author details
1Ion Beam Centre, Faculty of Engineering & Physical Sciences, University of
Surrey, Guildford, Surrey GU2 7XH, UK. 2Oncology Centre, Addenbrooke’s
Hospital, PO Box 193, Cambridge CB2 0QQ, UK. 3Department of Oncology,
University of Cambridge, Oncology Centre, Addenbrooke’s Hospital, PO Box
193, Cambridge CB2 0QQ, UK. 4Department of Biochemistry and Physiology,
Faculty of Health & Medical Sciences, University of Surrey, Guildford, Surrey
GU 7XH, UK. 5Chemical and Process Engineering, Faculty of Engineering &
Physical Sciences, University of Surrey, Guildford, Surrey GU 7XH, UK.
Received: 9 November 2012 Accepted: 12 March 2013
Published: 19 March 2013References
1. Burnet NG, Jefferies SJ, Benson RJ, Hunt DP, Treasure FP: Years of life lost
(YLL) from cancer is an important measure of population burden and
should be considered when allocating research funds. Br J Cancer 2005,
92:241–245.
2. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ,
Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC,
Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E,
Mirimanoff RO: European Organisation for Research and Treatment
of Cancer Brain Tumor and Radiotherapy Groups; National Cancer
Institute of Canada Clinical Trials Group: Radiotherapy plus concomitant
and adjuvant temozolomide for glioblastoma. N Engl J Med 2005,
352:987–996.
3. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM,
Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO,
Cairncross JG, Janzer RC, Stupp R: MGMT gene silencing and benefit from
temozolomide in glioblastoma. N Engl J Med 2005, 352:997–1003.
4. Helleday T, Petermann E, Lundin C, Hodgson B, Sharma RA: DNA repair
pathways as targets for cancer therapy. Nat Rev Cancer 2008, 8:193–204.
5. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, Bontcheva-
Diaz VD, Cox BF, DeWeese TL, Dillehay LE, Ferguson DC, Ghoreishi-Haack
NS, Grimm DR, Guan R, Han EK, Holley-Shanks RR, Hristov B, Idler KB, Jarvis
K, Johnson EF, Kleinberg LR, Klinghofer V, Lasko LM, Liu X, Marsh KC,
McGonigal TP, Meulbroek JA, Olson AM, Palma JP, Rodriguez LE, Shi Y,
Stavropoulos JA, Tsurutani AC, Zhu GD, Rosenberg SH, Giranda VL, Frost DJ:
ABT-888, an orally active poly(ADPribose) polymerase inhibitor that
potentiates DNA-damaging agents in preclinical tumor models. Clin
Cancer Res 2007, 13:2728–2737.
6. Barazzuol L, Jena R, Burnet NG, Jeynes JC, Merchant MJ, Kirkby KJ, Kirkby NF:
In vitro evaluation of combined temozolomide and radiotherapy using X
rays and high-linear energy transfer radiation for glioblastoma. Radiat Res
2012, 177:651–662.
7. Kirkby KJ, Grime GW, Webb RP, Kirkby NF, Folkard M, Prise K, Vojnovic B: A
scanning focussed vertical ion nanobeam: A new UK facility for cell
irradiation and analysis. Nucl Instrum Meth B 2007, 260:97–100.
8. Clinical trial registry. http://clinicaltrials.gov/.
9. Clarke MJ, Mulligan EA, Grogan PT, Mladek AC, Carlson BL, Schroeder MA,
Curtin NJ, Lou Z, Decker PA, Wu W, Plummer ER, Sarkaria JN: Effective
sensitization of temozolomide by ABT-888 is lost with development oftemozolomide resistance in glioblastoma xenograft lines. Mol Cancer Ther
2009, 8:407–414.
10. Albert JM, Cao C, Kim KW, Willey CD, Geng L, Xiao D, Wang H, Sandler A,
Johnson DH, Colevas AD, Low J, Rothenberg ML, Lu B: Inhibition of poly
(ADP-ribose) polymerase enhances cell death and improves tumor
growth delay in irradiated lung cancer models. Clin Cancer Res 2007,
13:3033–3042.
11. Horton TM, Jenkins G, Pati D, Zhang L, Dolan ME, Ribes-Zamora A, Bertuch
AA, Blaney SM, Delaney SL, Hegde M, Berg SL: Poly(ADP-ribose)
polymerase inhibitor ABT-888 potentiates the cytotoxic activity of
temozolomide in leukemia cells: influence of mismatch repair status and
O6-methylguanine-DNA methyltransferase activity. Mol Cancer Ther 2009,
8:2232–2242.
12. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR,
Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos
H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow
JH: Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor
ABT-888 in Patients With Advanced Malignancies. J Clin Oncol 2009,
27:2705–2111.
13. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza
G, Murgo AJ, Kinders R, Wang L, Parchment RE, Carter J, Stotler H,
Rubinstein L, Hollingshead M, Melillo G, Pommier Y, Bonner W, Tomaszewski
JE, Doroshow JH: Phase I Study of PARP Inhibitor ABT-888 in
Combination with Topotecan in Adults with Refractory Solid Tumors and
Lymphomas. Cancer Res 2011, 71:5626–5634.
14. Valenzuela MT, Guerrero R, Núñez MI, Ruiz De Almodóvar JM, Sarker M, de
Murcia G, Oliver FJ: PARP-1 modifies the effectiveness of p53-mediated
DNA damage response. Oncogene 2002, 21:1108–1116.
15. Wieler S, Gagné JP, Vaziri H, Poirier GG, Benchimol S: Poly(ADPribose)
polymerase-1 is a positive regulator of the p53-mediated G1 arrest
response following ionizing radiation. J Biol Chem 2003, 278:18914–18921.
16. The Cancer Genome Atlas (TCGA) Research Network: Comprehensive
genomic characterization defines human glioblastoma genes and core
pathways. Nature 2008, 455:1061–1068.
17. Chalmers AJ: Overcoming resistance of glioblastoma to conventional
cytotoxic therapies by the addition of PARP inhibitors. Anticancer Agents
Med Chem 2010, 10:520–533.
18. Noël G, Godon C, Fernet M, Giocanti N, Mégnin-Chanet F, Favaudon V:
Radiosensitization by the poly(ADP-ribose) polymerase inhibitor 4-amino
-1,8-naphthalimide is specific of the S phase of the cell cycle and
involves arrest of DNA synthesis. Mol Cancer Ther 2006, 5:564–574.
19. Dungey FA, Lӧ ser DA, Chalmers AJ: Replication-dependent
radiosensitization of human glioma cells by inhibition of poly
(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J
Radiat Oncol Biol Phys 2008, 72:1188–1197.
20. Efimova EV, Mauceri HJ, Golden DW, Labay E, Bindokas VP, Darga TE,
Chakraborty C, Barreto-Andrade JC, Crawley C, Sutton HG, Kron SJ,
Weichselbaum RR: Poly(ADP-ribose) polymerase inhibitor induces
accelerated senescence inirradiated breast cancer cells and tumors.
Cancer Res 2010, 70:6277–6282.
21. Liu SK, Coackley C, Krause M, Jalali F, Chan N, Bristow RG: A novel poly
(ADP-ribose) polymerase inhibitor, ABT-888, radiosensitizes malignant
human cell lines under hypoxia. Radiother Oncol 2008, 88:258–268.
22. Wilson GD, Bentzen SM, Harari PM: Biologic basis for combining drugs
with radiation. Semin Radiat Oncol 2006, 16:2–9.
23. Hei TK, Piao CQ, Geard CR, Hall EJ: Taxol and ionizing radiation: interaction
and mechanisms. Int J Radiat Oncol Biol Phys 1994, 29:267–271.
24. Palma JP, Wang YC, Rodriguez LE, Montgomery D, Ellis PA, Bukofzer G,
Niquette A, Liu X, Shi Y, Lasko L, Zhu GD, Penning TD, Giranda VL,
Rosenberg SH, Frost DJ, Donawho CK: ABT-888 confers broad in vivo
activity in combination with temozolomide in diverse tumors. Clin Cancer
Res 2009, 15:7277–7290.
25. van Rijn J, Heimans JJ, van den Berg J, van der Valk P, Slotman BJ: Survival
of human glioma cells treated with various combination of
temozolomide and X-rays. Int J Radiat Oncol Biol Phys 2000, 47:779–784.
26. Chakravarti A, Erkkinen MG, Nestler U, Stupp R, Mehta M, Aldape K, Gilbert
MR, Black PM, Loeffler JS: Temozolomide-mediated radiation
enhancement in glioblastoma: a report on underlying mechanisms.
Clin Cancer Res 2006, 12:4738–4746.
27. van Nifterik KA, van den Berg J, Stalpers LJ, Lafleur MV, Leenstra S, Slotman
BJ, Hulsebos TJ, Sminia P: Differential radiosensitizing potential of
Barazzuol et al. Radiation Oncology 2013, 8:65 Page 11 of 11
http://www.ro-journal.com/content/8/1/65temozolomide in MGMT promoter methylated glioblastoma multiforme
cell lines. Int J Radiat Oncol Biol Phys 2007, 69:1246–1253.
28. Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, Tofilon PJ,
Camphausen K: In vitro and in vivo radiosensitization induced by the
DNA methylating agent temozolomide. Clin Cancer Res 2008, 14:931–938.
29. Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES: In vitro
evaluation of temozolomide combined with X-irradiation. Anti-cancer
drugs 1997, 8:92–97.
30. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B,
Weller M: O6-methylguanine DNA methyltransferase and p53 status
predict temozolomide sensitivity in human malignant glioma cells.
J Neurochem 2006, 96:766–776.
31. Combs SE, Schulz-Ertner D, Roth W, Herold-Mende C, Debus J, Weber KJ: In
vitro responsiveness of glioma cell lines to multimodality treatment with
radiotherapy, temozolomide, and epidermal growth factor receptor
inhibition with cetuximab. Int J Radiat Oncol Biol Phys 2007, 68:873–882.
32. Chalmers AJ, Ruff EM, Martindale C, Lovegrove N, Short SC: Cytotoxic
effects of temozolomide and radiation are additive- and schedule-
dependent. Int J Radiat Oncol Biol Phys 2009, 75:1511–9.
33. Liu X, Shi Y, Guan R, Donawho C, Luo Y, Palma J, Zhu GD, Johnson EF,
Rodriguez LE, Ghoreishi-Haack N, Jarvis K, Hradil VP, Colon-Lopez M, Cox BF,
Klinghofer V, Penning T, Rosenberg SH, Frost D, Giranda VL, Luo Y:
Potentiation of temozolomide cytotoxicity by poly(ADP)ribose
polymerase inhibitor ABT-888 requires a conversion of single-stranded
DNA damages to doublestranded DNA breaks. Mol Cancer Res 2008,
6:1621–1629.
34. Nowsheen S, Bonner JA, Lobuglio AF, Trummell H, Whitley AC, Dobelbower
MC, Yang ES: Cetuximab augments cytotoxicity with poly (ADPribose)
polymerase inhibition in head and neck cancer. PLoS One 2011, 6:1–11.
35. Huehls AM, Wagner JM, Huntoon CJ, Geng L, Erlichman C, Patel AG,
Kaufmann SH, Karnitz LM: Poly(ADP-ribose) polymerase inhibition
synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian
cancer cells. Cancer Res 2011, 71:4944–4954.
doi:10.1186/1748-717X-8-65
Cite this article as: Barazzuol et al.: Evaluation of poly (ADP-ribose)
polymerase inhibitor ABT-888 combined with radiotherapy and
temozolomide in glioblastoma. Radiation Oncology 2013 8:65.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
